A specific FMNL2 isoform is up-regulated in invasive cells by Christine Péladeau et al.
RESEARCH ARTICLE Open Access
A specific FMNL2 isoform is up-regulated in
invasive cells
Christine Péladeau, Allan Heibein, Melissa T. Maltez, Sarah J. Copeland and John W. Copeland*
Abstract
Background: Formins are a highly conserved family of cytoskeletal remodeling proteins. A growing body of
evidence suggests that formins play key roles in the progression and spread of a variety of cancers. There are 15
human formin proteins and of these the Diaphanous-Related Formins (DRFs) are the best characterized. Included in
the DRFs are the Formin-Like proteins, FMNL1, 2 & 3, each of which have been strongly implicated in driving
tumorigenesis and metastasis of specific tumors. In particular, increased FMNL2 expression correlates with increased
invasiveness of colorectal cancer (CRC) in vivo and for a variety of CRC cell-lines in vitro. FMNL2 expression is also
required for invasive cell motility in other cancer cell-lines. There are multiple alternatively spliced isoforms of
FMNL2 and it is predicted that the encoded proteins will differ in their regulation, subcellular localization and in
their ability to regulate cytoskeletal dynamics.
Results: Using RT-PCR we identified four FMNL2 isoforms expressed in CRC and melanoma cell-lines. We find that a
previously uncharacterized FMNL2 isoform is predominantly expressed in a variety of melanoma and CRC cell lines;
this isoform is also more effective in driving 3D motility. Building on previous reports, we also show that FMNL2 is
required for invasion in A375 and WM266.4 melanoma cells.
Conclusions: Taken together, these results suggest that FMNL2 is likely to be generally required in melanoma cells
for invasion, that a specific isoform of FMNL2 is up-regulated in invasive CRC and melanoma cells and this isoform
is the most effective at facilitating invasion.
Keywords: Formins, Actin, Invasion, Metastasis, FMNL2, Melanoma, Colorectal cancer
Abbreviations: CRC, Colorectal cancer; DAD, Diaphanous Autoregulatory domain; DID, Diaphanous inhibitory
domain; DRF, Diaphanous-Related Formin; FH, Formin homology; FMNL, Formin-like; MT, Microtubules;
qPCR, quantitative PCR; RT-PCR, Reverse transcription PCR; SRF, Serum Response Factor
Background
Metastasis initiates with the migration of individual cells,
or cellular collectives, from the tumor into the sur-
rounding stroma [1]. Individually invading tumor cells
use either a mesenchymal or amoeboid mode of 3-D mi-
gration. In this context, mesenchymal invasion requires
low actomyosin contractility, greater cell-substrate at-
tachment, and proteolytic digestion of the extracellular
matrix. In contrast, amoeboid invasion requires high
contractility, low adhesion and is protease-independent
[2, 3]. A specific cell-type utilizes a specific mode of in-
vasion, however, cells will switch from mesenchymal to
amoeboid migration when mesenchymal motility is
inhibited [4]. In vivo, amoeboid invasion is very rapid
and is used by breast cancer cells to invade the stroma
[5]. In vitro, a variety of colorectal and melanoma cancer
cell lines adopt this mode of migration [3, 6]. Both 2D
and 3D cell motility is driven by the coordinated regula-
tion of actin dynamics and is dependent upon a variety
of actin remodeling proteins.
Formin homology proteins are a highly conserved fam-
ily of cytoskeletal remodeling proteins distinguished by
the presence of two functional domains, formin hom-
ology 1 (FH1) and FH2. FH1 is proline-rich and a ligand
for the small actin-binding protein profilin [7]. FH2
directly nucleates actin polymerization, inducing the for-
mation of long, unbranched actin filaments (F-actin);
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some FH2 domains also bind and bundle F-actin [8–11].
FH2 is a dual purpose domain that is also able to regu-
late microtubule (MT) stabilization [12–14].
Given their dramatic effects on cytoskeletal dynamics, it
is not surprising that a number of formins have been
shown to play a role in metastasis and invasion [1]. In par-
ticular, the FMNL sub-group of Diaphanous-Related For-
mins have each been shown to be required for migration
and invasion by transformed cells. FMNL1 promotes pro-
liferation and motility of leukemia cells [15–17]. FMNL3 is
required for invasion in PC3 prostate cancer cells and
down-regulation of FMNL3 expression is associated with
suppression of metastasis [18–21]. Increased FMNL2 ex-
pression correlates with increased invasiveness in CRC
cell-lines [22–24] and FMNL2 is consistently highly
expressed across the NCI60 panel of melanoma cell-lines
[25]. In patient samples increased FMNL2 expression also
correlates directly with increased CRC metastasis [23, 24].
FMNL2 is required in both MDA-MB-435 for amoeboid
cell invasion in vitro and B16-F1 melanoma cells where it
cooperates with the Arp2/3 complex for lamellipodial ex-
tension [6, 26]. More recently, FMNL2 has been shown to
participate in the regulation of cell-cell and cell-substrate
adhesions [27, 28].
The ability of FMNL2 to govern cytoskeletal dynamics
is regulated by an autoinhibitory interaction between its
C-terminal Diaphanous Autoregulatory Domain (DAD)
and N-terminal Diaphanous Inhibitory Domain (DID)
[11]. Inhibition is relieved by binding of either active
RhoC or cdc42 to the FMNL2 GTPase Binding Domain
(GBD) [6, 26]. Deletion of either DID or DAD is suffi-
cient to render FMNL2 constitutively active [11]. As
with other formins, constitutively active derivatives of
FMNL2 are able to induce F-actin accumulation and
MT acetylation in vivo [11, 12] as well as bind and bun-
dle actin filaments and accelerate F-actin polymerization
in vitro [11, 26]. F-actin bundling by FMNL2 is
dependent on FH2 and an actin-binding WH2 motif im-
mediately C-terminal to the FH2 domain [11]. The
FMNL2 protein is targeted to the plasma membrane by
N-myristoylation at Gly2 [29], although there are con-
flicting reports as to whether or not this modification is
required for FMNL2-dependent cell migration [22, 26].
Many formin genes undergo alternative splicing of
their mRNA and the resulting isoforms have significant
impact on the regulation, localization and function of
the encoded proteins [30–34]. Similarly, up-regulation of
a specific splice form of the cytoskeletal remodeling pro-
teins Mena and palladin potentiates the invasive pheno-
type of transformed cells [35–38]. There are at least 14
predicted alternative splice forms of FMNL2 affecting
regions that are likely to impact on the activity, regula-
tion and subcellular localization of the encoded proteins.
We show here that there are at least four of the
predicted FMNL2 isoforms expressed in CRC and mel-
anoma cells and that a novel isoform is preferentially
up-regulated in invasive cells. We also show that inva-
sion by A375 and WM266.4 melanoma cells is FMNL2-
dependent suggesting that FMNL2 might be generally
required for 3D invasion in this cell-type. All four
FMNL2 isoforms are able to rescue invasion in FMNL2-
depleted A375 cells, but the “invasive” isoform is signifi-
cantly better than the other three.
Methods
Cell culture
U2OS osteosarcoma human cells were a gift from Dr.
Laura Trinkle-Mulcahy and were grown in DMEM 10 %
FBS at 37 °C, in 5 % CO2. All other cell-lines were ob-
tained from the American Type Culture Collection
(ATCC) and were maintained as recommended by the
supplier.
Plasmids
The FMNL2 isoforms described in this study correspond to
the following accession numbers. ITM: NP_443.137.2, YHY:
Q96PY5, PMR: XP_005246322, TQS: XP_005246320.1.
Full length (FL) FMNL2 isoform cDNA were assembled
in a step-wise fashion into the pEF-plink2-mCherry vec-
tor. Briefly, the alternative 3′ ends of each FMNL2 iso-
form was amplified by polymerase chain reaction (PCR)
from cDNA generated from SW620 cell mRNA. The con-
served 5′ portion of the FMNL2 cDNA was amplified
from KIAA1902 (Kazusa Project, Japan). FMNL2 FH1 +
FH2 derivatives were subcloned into pEF.NBRSS from the
full-length constructs. For rescue, FMNL2 full-length iso-
forms were cloned into pLVX-IRES-mCherry lentivirus
vector. All PCR reactions were performed using standard
techniques and the Phusion High Fidelity DNA Polymer-
ase (Thermo scientific).
Serum Response Factor (SRF) assay
SRF reporter gene assays were performed as described
previously (Copeland and Treisman [39]). Briefly, NIH
3T3 fibroblasts were seeded on 6-well plates at 125 000
cells/well 1 day prior to transfection. The cells were
transfected using polyethylenimine transfection reagent
(PEI) with the indicated expression plasmids (0.1ug) and
the reporter constructs p3D.A.Luc (50 ng/well) and
pMLVLacZ (250 ng/well). After 5 h, the cells were
placed in low serum medium (0.5 % FBS in DMEM).
Cells were harvested the next day and lysed in 1x
Reporter Lysis buffer; luciferase assays were performed
according to the supplied protocol (Promega) and read
in an LMAXII Luminometer (Molecular Devices). The
activation of luciferase was standardized to an SRF-VP16
control. A β-galactosidase (β-gal) assay is performed in
parallel as a transfection efficiency control. The cell
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lysates are also subjected to a sodium dodecyl sulfate
polyacrylamide gel (SDS-PAGE) and immunoblotted to
detect FMNL2 expression levels.
RNA extraction, RT-PCR, and qPCR
The indicated cell-lines were grown to 70–80 % conflu-
ence in 10 cm dishes. Total RNA was harvested using
the RNeasy mini kit (Qiagen). Total RNA concentration
was determined by reading the OD280. RNA quality was
assessed on denaturing formaldehyde/agarose MOPS gel
and visualization of distinct 18S and 28S ribosomal sub-
units. cDNA were synthesized using MuLV reverse tran-
scriptase and the GeneAmp RNA PCR kit (Applied
Biosystems). PAW109 RNA serves as a positive RT-PCR
control and no RNA (ddH20) served as negative control.
Characterization of the FMNL2 isoforms in A375,
SW620 and SW480 cancer cell lines was accomplished
by performing a PCR reaction [2 mM MgCL2 solution,
1X PCR buffer I, ddH2O, 2.5U/100 μL AmpliTaq DNA
Polymerase, 20 μL purified cancer cell cDNA and
0.15 μM of both forward and reverse FMNL2 or control
specific primers]. PCR products were separated on 1 %
agarose gels. Amplified bands were isolated with Gen
Elute Gel extraction kit (Sigma) and directly sequenced.
These sequences were used to design primers for qPCR.
Real time PCR analysis was performed to determine
absolute expression levels of FMNL2 isoforms using the
following primers. ITM forward 5′-GCCATTGAAGA
TATTATCACAGATC-3′, rev 5′-AACTTGCGTTCTGT
TAATGGTG-3′, amplicon 117 bp; YHY 5′-CTGAAGA
CTGTGCCCTTTACTGCT-3′, 5′-CCTGTTCTCACTG
AGGAATACCATTAC-3′, amplicon 87 bp; PMR 5′-CA
TTGAAGATATTATCACAGCCTTA-3′, 5′-GAGGATC
TTAGAAACCAACCATA-3′, amplicon 87 bp; TQS 5′-G
ATATTATCACAGCCTTAAAGAAGAAT-3′, 5′-TGGTG
GAGGATACACAGAGCT-3′, amplicon 106 bp; pan-FM
NL2 5′-GCTCCTCCCTTAGCACCT-3′, 5′-GCCAATCA
AGACGAAGTTCAGA-3′, amplicon 127 bp; β-actin 5′-G
CACCACACCTTCTACAATGAG-3′, 5′-GACCCAGATC
ATGTTTGAGACC-3′, amplicon 122 bp. Standard curves
were established using FMNL2 FH1 + FH2 +C templates
corresponding to each isoform. A logarithmic series of
template dilutions were generated (102, 103, 104, 105, 106
copies per tube). A standard curve for β-actin template
was also generated as a control. The experimental design
included standards, no template controls and unknowns.
Standards contained: 5 μL FMNL2 isoform template, 5 μL
of specific FMNL2 isoform primer (final concentration:
300 ng/well/primer) and 10 μL of the SYBR Green PCR
Premix (QuantiTect; QIAGEN) used according to the
manufacturer’s instructions. Unknown reactions consisted
of 5 μL cDNA (harvested from cancer cell lines) (0.05 μg/
tube), 5 μL primers and 10 μL SYBR Green qPCR Premix.
No template control reactions were 5 μL of primers, 10 μL
of SYBR Green mix and 5 μL ddH2O. 5-carboxy-X-Rhoda-
mine (ROX) is also included in the SYBR Green qPCR
Premix and serves as a passive loading reference dye. The
qPCR reactions were run on an Mx 3005P qPCR instru-
ment (Stratagene). Standard curves for each isoform were
used to determine the relationship between the fluorescent
signal (the CT value) and absolute copy number of each
FMNL2 isoforms in each sample.
Immunofluorescence
NIH-3T3 fibroblast cells were seeded at a density of 125
000 cells/well in 6-well plates containing acid-washed
coverslips and 10 % DBS DMEM medium. The cells
were transfected using PEI (1 mg/mL) as above. 24 h
later, the cells were fixed with 4 % paraformaldehyde
(PFA) in PBS for 15 min, washed three times with 1x
PBS (5 min) and permeabilized for 30 min with 0.3 %
Triton X-100, 10 % horse serum in 1XPBS. Fixed cells
were incubated at room temperature with primary anti-
bodies in 0.03 % Triton X-100 plus 5 % horse serum 1X
PBS for 1 h. Cells were washed three times in 1X PBS
and incubated with the appropriate secondary antibody
and Fluorescein-Phalloidin (1:100, Molecular Probes) in
0.03 % Triton X-100 plus 5 % horse serum 1X PBS at
room temperature for 1 h. The cells were washed three
times in 1X PBS and once in ddH2O and mounted on
slides with Vectashield mounting medium with DAPI
(Vector Laboratories). Images were captured on a Zeiss
Axio Imager Z1 fluorescence microscope, using a 63X
Plan Apochromat objective and an AxioCam HRm cam-
era. Optical sections were obtained with the apotome2.
Images were processed using Axiovision software and
figures assembled using Adobe Photoshop.
Filopodia formation in transfected cells was assessed visu-
ally by immunofluorescence. Transfected cells expressing
myr-mCherryFP or FMNL2-mCherry were identified by
virtue of the mCherryFP tag and F-actin visualized by
fluorescein-phalloidin as above. Cells with an obvious over-
proliferation of filopodia (>25 filopodia/cell) compared to
either non-transfected neighbours or myr-mCherryFP
expressing control cells were counted and the result
expressed as a percent of transfected cells.
Western blotting
Cells were grown to 70–80 % confluence in 10 cm dishes,
washed with 1XPBS and harvested in 1xSDS buffer.
Lysates were subjected to SDS-PAGE and immunoblotted
with the indicated antibodies. Chemiluminescence was
used for detection using the western HRP substrate reagent
(Millipore) and visualized on a GE Image Quant LAS4010
Imaging System. Blots were stripped in 0.1 M Glycine,
0.5 % SDS (pH2.5) for 1 h. Blots were re-blocked and
probed with mouse-anti-α-tubulin (clone DM1A, T9026,
Sigma) to assess loading. Chemiluminescence and
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visualization is performed as described previously. Pan-
FMNL2 antiserum was raised in chicken (Cedarlane) using
the isolated FMNL2-FH2 protein (codons 599–1045)
expressed in E.coli and purified as previously described
[11]. All FMNL2 antisera were affinity purified using stand-
ard protocols [40]. Affinity purified anti-FMNL3 antibody
was described previously [41].
FMNL2 siRNA
A375 or WM266.4 melanoma cells were seeded in six well
plates or 3.5 cm dishes (Corning) at a density of 125 000
cells/well. The following day, cells were transfected
(DharmaFECT #1, Thermo Scientific) with control or
FMNL2 siRNA duplexes (TriFECTa Dicer-Substrate
RNAi Kit, Integrated DNATechnologies) as directed by the
manufacturer. The siRNA duplex targeted the 3′UTR of
FMNL2 (5′-CCUGUUCAGAUUAAUCAAAGCAATA-3′).
A non-specific universal negative control duplex (Inte-
grated DNA Technologies) was used for all siRNA knock-
down experiments. This control duplex does not recognize
any sequences in human, mouse or rat transcriptomes
(5′-CGUUAAUCGCGUAUAAUAAGAGUAT-3′). Follow-
ing transfection, cells were incubated at 37 °C (5 % CO2)
for 48 h. A fluorescent TYE 563 DS control was used to
verify transfection efficiency. After 48 h, cells are harvested
and the lysates subjected to immunoblotting to detect
FMNL2 expression levels.
2-D migration assay
A375 melanoma cells were seeded in six well plates or
3.5 cm petri dish (Corning) at a density of 125,000 cells/
well. The following day, the cells were transfected with
siRNA; after 48 h 100,000 A375 cells were added to each
chamber of an ibidi wound insert in a 3.5 cm petri dish
(Ibidi). The outside of the insert was filled with 1.5 ml of
DMEM 10 % FBS. In parallel, cells were also seeded in
duplicate to assess knockdown efficiency by immuno-
bloting. The next day, the insert was removed to gener-
ate the wound and the plate was gently washed with
10 % FBS DMEM to remove any floating cells. Wound
closure was monitored for 48 h by live imaging on a
Zeiss Axiovert 200 microscope (10x objective, phase 1)
in a controlled environment (5 % CO2, 37 °C). The
percent wound closure was calculated by measuring the
distance of the gap at three points using Northern
Eclipse Software (NES, Empix Imaging, Mississauga, On-
tario, Canada).
Virus production and transduction
FMNL2 cDNA were cloned into the lentiviral vector
pLVX-IRES-mCherry for virus production. Briefly, 10
plates (15 cm) of 293 T cells at 70 % confluence were
transfected with 96.85 μg of the FMNL2 pLVX-IRES-
mCherry construct, 53.95 μg of the envelop plasmid
(pMD2G coding for VSV-G envelope), 99.15 μg of the
packaging plasmid psPAX2 using PEI. Virus was col-
lected from the medium supernatant every day for the
next 48 h. The virus was concentrated and titrated to
determine the multiplicity of infection (MOI). For rescue
experiments, A375 melanoma cells were seeded at a
density of 125 000 cells/well, in a six well plate or in a
3.5 cm petri dish with a coverslip. The next day, the cells
were transfected with siRNAs and incubated for 24 h be-
fore infection with the FMNL2 expressing lentiviral
vectors using a multiplicity of infection (MOI) of 10. The
cells were left for another 24 h before seeding for an in-
vasion assay. Efficiency of knockdown and re-expression
of FMNL2 was assessed by immunoblotting and im-
munofluorescence on parallel samples.
Transwell invasion assay
6.5 mm/8 μm transwell inserts (Costar #3422) were
coated with 100 μL of 1:1 DMEM:growth factor reduced
Matrigel (#356230) and allowed to polymerize for 1 h at
37 °C. The polymerized transwells were flipped upside
down and the underside coated with 50 μL of a 1:20
matrigel: DMEM solution to facilitate cell adhesion and
placed back into the 37 °C incubator for 1 h. 7000 A375
cells in 70 μL of DMEM (0.5 % FBS) were seeded on the
underside of the inserts and allowed to adhere for 3 h at
37 °C. The inserts were then flipped into a 24 well plate
containing 600 μL of DMEM (0.5 % FBS) on the bottom.
200 μL of 20 % FBS DMEM was carefully added to the
top of the insert. Cells were left to invade through the
matrigel at 37 °C (5 % CO2) for 72 h. The cells were
then fixed with CSK buffer (containing 8 % paraformal-
dehyde) for 30 min, washed with PBS and then perme-
abilized with 0.3 % Triton X-100 for another 30 min.
The cells were stained with 50 μg/mL of Propidium
Iodide overnight at 4 °C. The transwells were then gently
washed in PBS, rinsed in ddH2O, and then placed onto a
35 mm Mat-Tek coverslip culture dish with 15 μL Vecta-
shield (Vector Labs). Cells were imaged on a Zeiss
LSM.Pascal using a 40x NA1.30 oil objective. 100 optical
sections were taken (50 slices before the transwell mem-
brane and 50 slices into the matrigel) with the Z step set
at Nyquist sampling frequency (~0.5 μM/slice) and total
number of cells counted in each section to determine
invasion frequency.
Results
There are 14 human FMNL2 isoforms listed in the
NCBI protein database at present. These isoforms are
generated by alternative splicing of their mRNA and the
exons affected encode both functional and regulatory
domains in the FMNL2 protein. Therefore we wished to
determine which FMNL2 isoforms are expressed in cell-
types relevant to the study of the role of FMNL2 in
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invasion and metastasis. A series of overlapping primer
pairs was designed to span the entire FMNL2 coding
sequence with attention paid to regions bridging the
predicted alternative splice sites. These primers were
used to amplify individual sections of the entire FMNL2
coding sequence using cDNA prepared from SW480 to
SW620 colorectal cancer, and A375 melanoma, cell-
lines. The resulting amplified fragments were gel-
purified and sequenced directly. From this analysis only
four FMNL2 alternatively spliced isoforms were detected
and these varied only at the 3′ end of the coding
sequence (see Experimental Procedures for accession
numbers). Based on sequence analysis, additional primer
pairs were designed to confirm these results directly and
to amplify these sequences specifically (Fig. 1a). The pro-
teins encoded by the alternatively spliced mRNA differ
only in the region C-terminal to the autoregulatory
DAD domain and are designated ITM, PMR, YHY, and
TQS for the final three C-terminal amino acid residues
of each protein (Fig. 1b). It should be noted that add-
itional alternatively spliced versions of FMNL2 are listed
in the NCBI database, however, all of these splicing
events are predicted to affect other regions of the coding
sequence, that is, there are no additional 3′ splice vari-
ants predicted that encode additional alternative C-
terminal tails. No other splice variants were detected in
our assays.
In our initial RT-PCR analysis we noted apparent vari-
ations in the relative abundance of the different FMNL2
splice forms (Fig. 1a). Therefore we wished to determine
the expression levels of each isoform in a panel of rele-
vant cell-lines chosen either for utilizing an amoeboid
mode of migration, or for their tissue of origin (CRC
and melanoma). Primary HUVECs, primary melano-
cytes, A431 carcinoma and U2OS osteosarcoma cells
were also included for comparison. Primers unique to
each alternatively spliced isoform were designed for
qPCR analysis and amplification efficiency was calibrated
using the relevant cloned cDNA. Validated primer sets
were obtained for the linear amplification of total
FMNL2, ITM, YHY and TQS, however, we were unable
to generate primers for the specific linear amplification
of PMR. The cloned cDNA were also used to generate
standard curves that allowed the derivation of absolute
copy number for each isoform in the various cell-lines.
Consistent with previous reports [23], we confirmed that
FMNL2 expression is elevated in the metastatic SW620
cell-line when compared to parental SW480 cells
(Fig. 1c). We also detected similar elevated levels of ex-
pression in LS174T CRC cells, as well as A375 and
WM266.4 melanoma cells (Fig. 1c). We were unable to
detect FMNL2 mRNA in U2OS cells and only low levels
of FMNL2 mRNA in primary HUVECs. Surprisingly, the
total level of FMNL2 expression in primary melanocytes
was similar to that in the melanoma cell-lines. Spe-
cific, individual measurement of the separate FMNL2
isoforms indicated that TQS was essentially the sole
isoform expressed in A375, WM266.4 and SW620
cells and the major isoform in LS174T and A431
cells. In primary melanocytes, however, TQS accounts
for less than 50 % of total FMNL2 mRNA. We were
unable to assess levels of PMR expression in this
assay. Nevertheless, a comparison of total FMNL2
with the sum of the individual isoforms suggests that,
with the notable exception of primary melanocytes,
PMR does not contribute significantly to total FMNL2
mRNA levels.
We next wished to confirm the results of our qPCR
assays at the protein level. Total FMNL2 levels were
assessed using a pan-FMNL2 antibody recognizing an
invariant region in the N-terminus. We also generated
polyclonal antibodies raised against peptides correspond-
ing to the unique C-terminal tails of each of the four
FMNL2 isoforms (Fig. 1d). These antibodies were affinity
purified and used for immunoblot analysis of lysates
from the panel of cell-lines used in Fig. 1c. The pan-
FMNL2 immunoblot (Fig. 1e, top panel) largely con-
firmed the qPCR results, with highest levels of FMNL2
expression in primary melanocytes and metastatic
melanoma (A375 and WM266.4) and CRC (LS174T and
SW620) cell-lines. FMNL2 protein was not detected in
U2OS cell lysates. The isoform specific immunoblots
also showed that only primary melanocytes express a
mix of the four FMNL2 isoforms; significant levels of
YHY and PMR are not detected in the other cell-lines
and only low levels of ITM are detected across this
panel. In contrast, the TQS specific immunoblot shows
that it is the major isoform expressed in A375, SW620
and WM266.4 cell-lines.
Amino acid residues C-terminal to the DAD motif are
predicted to modulate formin autoregulation [9] and
modify FH2 activity [42]. To compare activity of the
FMNL2 isoforms, we generated full-length cDNAs
encoding each of the four splice variants. FMNL
proteins are predicted to be N-myristoylated [26, 29, 33]
and this modification may play some role in targeting
these proteins to the plasma membrane. To assess the
effects of N-myristoylation we generated FMNL2 deriva-
tives with either N-terminal myc epitope tags or C-
terminal mCherryFP tags. These were expressed in NIH
3T3 cells by transient transfection and their subcellular
localization and effects on cell morphology and the actin
cytoskeleton were assessed by immunofluorescence
(Fig. 2). The C-terminal tagged derivatives were re-
cruited to the plasma membrane where they induced
extensive filopodia formation (Fig. 2a, c). This was not
the case with the N-terminal tagged proteins, which
were distributed diffusely throughout the cytoplasm.
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Expression of N-terminal tagged versions of ITM, YHY
or TQS did not induce filopodia formation above the
background levels seen in control cells while expression
of PMR was only sufficient to induce filopodia formation
in a minority of cells (Fig. 2b, c). We also compared ac-
tivity of N- and C-terminal tagged proteins using an SRF
reporter gene assay. This reporter gene is activated by
the MRTF/SRF transcription pathway in response to
depletion of cellular pools of G-actin and is an indirect,
sensitive and quantitative measure of changes in actin
dynamics [39]. Neither N- nor C-terminal tagged full-
length derivatives of the FMNL2 isoforms induced
Fig. 1 A specific FMNL2 isoform is over-represented in invasive cells. a RT-PCR was performed on total RNA harvested from SW480, SW620 and
A375 cells. Specific primers were used to demonstrate the presence of four alternatively spliced FMNL2 isoforms identified in an initial RT-PCR
analysis (see Results). b The four alternatively spliced mRNA are predicted to encode proteins differing only at amino acid residues C-terminal to
the DAD domain. c qPCR was used to assess the levels of expression of each isoform in comparison to total FMNL2 in the indicated colorectal
and melanoma cell-lines as well as in non-transformed primary endothelial cells and melanocytes. The TQS isoform was predominant in all the
invasive cell-lines that were assessed. We were unable to obtain reliable qPCR data for the PMR isoform. d Isoform specific antibodies were raised
against peptides corresponding to the unique domain of each C-terminal tail. Full-length derivatives of the indicated FMNL2 isoforms bearing
N-terminal myc epitope tags were expressed in U2OS cells by transient transfection and the resulting cell lysates were immunoblotted with the
indicated antibodies. Total FMNL2 protein was detected using an antibody directed against FMNL2 codons 599–1045. Equivalent samples were
loaded on a separate gel and probed with α-myc antibodies. The α-FMNL2 blot was stripped and re-probed with α-TQS antibody; the α-myc blot
was stripped and re-probed with α-PMR antibody. Equivalent samples were loaded on separate gels to detect ITM and YHY e Immunoblot
analysis using antibodies directed against the C-terminal tails of each of the predicted FMNL2 isoforms confirms the qPCR analysis. Total FMNL2
protein was detected using pan FMNL2 antibody shown in 1D. Isoform specific antibodies were raised against peptides corresponding to the
unique domain of each C-terminal tail. Equivalent samples were loaded on separate gels to eliminate concerns regarding incomplete stripping.
The pan-FMNL2 blot was stripped and re-probed with anti α-tubulin for a loading control
Péladeau et al. BMC Cell Biology  (2016) 17:32 Page 6 of 12
robust activation of the SRF reporter in this assay sug-
gesting that, as expected, the full-length derivatives of
each isoform are not constitutively active. Some differ-
ences, however, were apparent between the four iso-
forms, both in terms of basal activity and the effects of
the position of the tag. PMR showed the most activity,
inducing activation of the SRF reporter gene to similar
levels above background for both N-and C-terminal
tagged derivatives (Fig. 2d). In contrast, the C-terminally
tagged full-length derivatives of ITM, YHY and TQS
Fig. 2 FMNL2 expression induces filopodia formation. a C-terminally tagged full-length derivatives of each FMNL2 isoform were expressed in NIH
3T3 fibroblasts by transient transfection. F-actin (green) was detected with phalloidin and FMNL2 expression (red) was detected by virtue of the C-
terminal mCherry tag. Nuclei were detected with DAPI (blue) in merged image. FMNL2 expression induced extensive filopodia formation in com-
parison to untransfected cells or cells expressing mCherryFP with an N-terminal myristoylation motif (top panel). b N-terminally tagged
full-length derivatives of each of the FMNL2 isoforms were expressed in NIH 3T3 cells by transient transfection. F-actin (green) was detected with
phalloidin and FMNL2 expression (red) was detected by virtue of the N-terminal myc tag. Expression of N-terminally tagged FMNL2 isoforms does
not induce filopodia formation. mCherryFP was included as a control (top panel) c Quantification of data shown in (a, b). “C” indicates C-terminal
mCherry tag, “N” indicates N-terminal myc tag. N = 3, >100 cells counted per sample, error bars = SEM. d NIH 3T3 fibroblasts were transiently trans-
fected with an SRF luciferase reporter gene and the indicated full-length FMNL2 derivative. “C” indicates C-terminal mCherry tag, “N” indicates N-
terminal myc tag. Reporter activation is expressed relative to an SRF-VP16 control fusion protein. N = 3, error bars = SEM. e Equivalent samples of
transfected cell lysates were subjected to SDS-PAGE and immunoblotted. Expression of the indicated FMNL2 isoforms was detected with either
anti-mCherry or anti-myc antibody
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were largely inactive, while the N-terminal tag on ITM
had a modest effect on its autoinhibition as well.
The results of the SRF reporter gene assays suggest
that the full-length FMNL2 isoforms are largely autoin-
hibited and that FMNL2-induced filopodia are likely a
product of basal levels of FMNL2-induced F-actin for-
mation on top of remodeling of pre-existing actin fila-
ments. We therefore also wanted to compare the activity
of constitutively active derivatives of the four isoforms.
Deletion derivatives consisting of FH1, FH2 and the C-
terminal tail (FH1FH2 + C) of each isoform were
expressed in NIH 3T3 cells by transient transfection and
the effects on cell morphology and actin polymerization
were assessed by immunofluorescence (Fig. 3a, b). All
four isoforms behaved similarly in this assay and in-
duced a typical “formin” phenotype with extensive for-
mation of thin stress fibers running from one end of the
cell to the other. No obvious differences were apparent
in the subcellular localization of each of these derivatives
either. The SRF reporter gene assay was also used to
compare the effects of each isoform on actin dynamics.
Expression of the FH1FH2 + C derivative of each isoform
was sufficient to induce robust SRF reporter gene activa-
tion consistent with previous results for ITM [11]. As
with the formation of stress fibers, there was no obvious
difference in the level of activation of the SRF reporter
induced by expression of each isoform.
Our preliminary analysis of the full-length FMNL2
isoforms suggested that there are some functional dif-
ferences between them (Fig. 2c, d). We wished to deter-
mine if this extends to their effects on cell behavior.
Previous work has suggested that FMNL2 is required
for both 2D and 3D cell motility in specific cell-types
[6, 26]. Therefore we wanted to determine if FMNL2 is
required for motility in A375 cells which express the
TQS isoform almost exclusively. We used siRNA du-
plexes targeted against FMNL2 to knockdown its ex-
pression in A375 cells and the level of depletion was
assessed by immunoblotting with an anti-FMNL2 anti-
body (Fig. 4b); cells transfected with non-specific
duplex were used as a control. FMNL2 expression was
knocked down very efficiently and the effects of FMNL2
depletion on cell motility were assessed using a variation
on the scratch wound assay. In this assay, cells were
seeded in a culture insert composed of two chambers sep-
arated by a divider and allowed to grow to confluence.
Removal of the insert creates a standard “wound” and mi-
gration into the wound is followed by live-cell imaging.
Control cells extensively infiltrated the wound by 20 h and
filled the wound by 40 h (Fig. 4a, c). In contrast, FMNL2-
depleted cells made little progress into the wound even
after 40 h (Fig. 4a, c). This suggests that FMNL2 plays a
role in 2D migration in A375 cells and encouraged us to
investigate if the same holds true for 3D invasion.
A375 and WM266.4 melanoma cells both invade using
an amoeboid mode of 3D migration [3]. To determine if
FMNL2 is required for 3D migration in these cells, we used
a modified Boyden chamber assay to measure invasion [6].
In this assay cells are seeded on the underside of a trans-
well insert and their ability to invade upward into a matri-
gel matrix is assessed by confocal microscopy. siRNA
duplexes were used to knockdown FMNL2 expression in
both A375 and WM266.4 cells and FMNL2 was efficiently
Fig. 3 Constitutively active derivatives of FMNL2 induce stress fiber
formation. a Schematic of FH1-FH2 + C containing derivatives of each
FMNL2 isoform. b FH1-FH2 + C containing derivatives of FMNL2 were
expressed in NIH 3T3 cells by transient transfection. Expression of each
of the FMNL2 isoforms (red) was sufficient to induce stress fiber
formation (F-actin, green). Nuclei were detected with DAPI in the
merged image. c NIH 3T3 fibroblasts were transiently transfected with
an SRF luciferase reporter gene and the indicated FMNL2 derivative.
Reporter activation is expressed relative to an SRF-VP16 control fusion
protein. N = 3, error bars = SEM. Equivalent samples of transfected cell
lysates were subjected to SDS-PAGE and immunoblotted using an
anti-myc antibody (inset)
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depleted in both cell-types as measured by immunoblot-
ting (Fig. 5b, c). FMNL2 depletion did not affect expression
levels of the related protein FMNL3 in A375 cells (Fig. 5b)
and expression of FMNL1 was not detected (data not
shown). The effect of FMNL2 depletion on the ability of
A375 and WM266.4 cells to invade was compared to con-
trol cells transfected with non-specific siRNA duplexes.
For both cell-types we found that FMNL2 depletion was
sufficient to significantly inhibit invasion in the Transwell
assay (Fig. 5a).
Having shown that FMNL2 is required for invasion in
these cells, we wanted to compare the relative ability of
each of the four FMNL2 isoforms to rescue invasion in
knockdown cells. A375 cells were selected for this
experiment as they were more invasive in our assay,
FMNL2 was efficiently knocked down, and the effect of
FMNL2 knockdown on invasion was more striking with
these cells than with WM266.4 (Fig. 5a–c). Lentiviral
rescue vectors were generated for ITM, YHY, PMR and
TQS. This vector does not encode an epitope tag on the
protein of interest, but does express mCherryFP as a
separate protein via an IRES within the same mRNA.
Empty vector expressing mCherry alone was used as a
control. Using these vectors we were able to achieve
nearly 100 % transduction efficiency in A375 cells. As
before, transfection of control siRNA duplex had no
effect on invasion while knockdown of FMNL2 strongly
inhibits it. Efficiency of knockdown, and inhibition of
invasion, is not affected by infection with the control
lentiviral vector in FMNL2-depleted cells (Fig. 5d–f ). In
contrast, expression of each of the individual FMNL2
isoforms was sufficient to rescue invasion. It should be
noted, however, that each isoform did not rescue to the
same extent. PMR was the least efficient, TQS was the
most efficient, while YHY and ITM fell in between.
Indeed, the enhanced invasion observed with TQS was
significantly greater than both the parental cell-line and
PMR-rescued cells (although not significantly different
from ITM or YHY). This suggests that there are unique
functional differences between FMNL2 isoforms when it
comes to driving invasive cell migration.
Discussion
We provide here the initial description of two previously
uncharacterized isoforms of FMNL2 (PMR and TQS)
and show that at least four alternatively spliced FMNL2
isoforms are expressed in primary melanocytes. In con-
trast, the TQS isoform predominates in invasive melan-
oma and CRC cell-lines and we find that knockdown of
FMNL2 expression in A375 and WM266.4 melanoma
cells is sufficient to inhibit invasion in an in vitro assay.
Taken with previous reports that FMNL2 is required for
Fig. 4 FMNL2 is required for 2-D migration in A375 melanoma cells. a A375 cells were transfected with either control siRNA duplex or duplexes
targeting all FMNL2 isoforms. The transfected cells were grown to confluence in scratch wound assay chambers (see Experimental Procedures).
Wound closure was followed at the indicated times by phase contrast live-cell microscopy. b Equivalent samples of cell lysates from (a) were
subjected to SDS-PAGE and immunoblotted to detect FMNL2 expression with anti-FMNL2 antibody. The pan-FMNL2 blot was stripped and
re-probed with anti α-tubulin as a loading control. c Quantification of the data shown in (a). The gap in the cellular monolayer is represented as
% wound closure. N = 3, error bars = SEM. ** indicates P < 0.01 and *** indicates P < 0.001
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migration in mouse B16 melanoma cells and for invasion
in MDA-MB-435 [6, 26], our results suggest that
FMNL2 is likely to be generally required for invasion in
melanoma cells. Like MDA-MB-435 cells, both A375
and WM 266.4 cells use an amoeboid mode of migration
for 3D invasion and these results suggest that this mode
of invasion might also generally require FMNL2 or
related activity [19].
At least four FMNL2 isoforms (ITM, YHY, PMR and
TQS) are expressed in the assessed cell-types at both the
transcript and protein level. Although we cannot dis-
count that additional isoforms may be expressed in other
cell-types, we did not find any evidence for additional
isoforms in our assays. In addition, the four unique C-
terminal tails we describe are the only C-termini pre-
dicted for all FMNL2 isoforms currently listed in the
NCBI database. Thus, the antiserum directed against
each unique FMNL2 C-terminal peptide should account
for all predicted isoforms of FMNL2. In primary mela-
nocytes all four splice forms were readily detected at the
Fig. 5 FMNL2 is required for invasion in A375 and WM266.4 melanoma cells. a A375 and WM266.4 melanoma cells were transfected with control or
FMNL2-specific siRNA duplexes. Control and knockdown cells were then assayed for their ability to invade in vitro in an inverted Boyden chamber assay
(Kitzing et al. [6]). FMNL2 knockdown inhibited invasion in both A375 and WM266.4 cells. b Equivalent samples of A375 cell lysates from (a) were subjected
to SDS-PAGE and immunoblotted to detect FMNL2 and FMNL3. The pan-FMNL2 blot was stripped and re-probed with anti α-tubulin as a loading control.
c Equivalent samples of WM266.4 cell lysates from (a) were subjected to SDS-PAGE and immunoblotted to detect FMNL2. The pan-FMNL2 blot was
stripped and re-probed with anti α-tubulin as a loading control. d A375 cells were transfected with control and FMNL2-targeted siRNA duplexes and then
infected with control lentiviral vector or lentiviral vectors expressing the indicated untagged full-length FMNL2 isoforms. The cells were then assayed for
their ability to invade as in (a). Images show a representative Z-stack projection from the invasion assays. e Equivalent samples of cell lysates from (d) were
subjected to SDS-PAGE and immunoblotted to detect FMNL2. α-tubulin was used as a loading control. f Quantification of data shown in (d). N= 3, error
bars = SEM. *indicates P< 0.05 where noted. There was no significant difference between TQS and ITM or TQS and YHY
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protein level, however, in WMM266.4, A375 and SW620
cells TQS is by far the predominant isoform. This raises
the intriguing possibility that TQS represents an “inva-
sive isoform” of FMNL2 similar to previous descriptions
of invasive isoforms of Mena [43] and palladin [35]. In
support of this hypothesis we find that in FMNL2-
depleted A375 cells, TQS is able to rescue invasion sig-
nificantly better than PMR and to a significantly higher
level than control cells. It should be noted that under
the conditions of the rescue experiment, the levels of
exogenous FMNL2 expression were considerably higher
than the endogenous protein and it is likely that the
system is saturated for FMNL2 activity. If that is the
case, it would suggest that the observed effects represent
the maximal potentiation of invasion by each isoform in
these cells.
Increased FMNL2 expression is reported to directly
correlate with increased invasiveness in colorectal cancer
cell-lines [23, 24]. Our results confirm this observation and
show that FMNL2 expression is up-regulated at both the
mRNA and protein level in SW620 CRC cells when com-
pared to their poorly invasive SW480 progenitor cell-line.
Indeed, the level of total FMNL2 expression in SW620 cells
is similar to that observed in the melanoma cell-lines.
Surprisingly, FMNL2 is expressed to comparable levels in
non-transformed primary melanocytes. As part of their
normal physiological role melanocytes themselves are
somewhat “invasive” and deliver melanosomes via wide-
spread formation of filopodia [44–46]. Given the ability of
FMNL2 to support invasion and induce filopodia forma-
tion, it might therefore be expected that elevated levels of
FMNL2 expression would also be required in these cells. A
key difference between the primary melanocytes and mel-
anoma cells, however, is the variety of FMNL2 isoforms
expressed. As noted, the TQS isoform predominates in
A375 and WM266.4 cells while at least four FMNL2
isoforms are expressed in primary melanocytes. This sug-
gests an intriguing model where it is not the total level of
FMNL2 expression that determines invasiveness in melan-
oma, but the specific isoform that is expressed.
The ITM, YHY, PMR and TQS isoforms of FMNL2 differ
only at a relatively small region in their C-termini. Never-
theless, the sequences affected are suggested to be critical
to the normal regulation and function of diaphanous-
related formins (DRFs); the domain C-terminal to DAD is
thought to influence both FH2 activity [42] and autoregula-
tion [9, 42]. Consistent with this, we find that auto-
inhibition of PMR is less efficient than the other three
isoforms and that TQS is the isoform most efficient at pro-
moting invasion. Beyond direct effects on FMNL2 activity,
the DRF C-terminus may also serve as a target for multiple
regulatory and accessory factors [10]. Indeed, a recent study
investigating the role of FMNL2 in integrin trafficking
found that the C-terminal tail of FMNL2.ITM is a target of
PKCα-dependent phosphorylation [28]. A comparison of
the four FMNL2 isoforms on the Eukaryotic Linear Motif
resource (http://elm.eu.org/index.html) reveals that the
PKCα site is conserved in the ITM and YHY isoforms, but
not in PMR or TQS. Instead the TQS C-terminal tail con-
tains consensus PKB and proline-directed kinase sites and
PMR contains no conserved kinase consensus sites at all.
This comparison suggests that the C-terminal tail of each
isoform is likely to be targeted by a variety of differing
upstream signaling pathways. Determining how the preva-
lence of each isoform affects the integration of specific sig-
naling pathways that regulate the effects of FMNL2 on cell
behavior will be of great future interest.
Conclusions
We show here that FMNL2 expression is required for inva-
sion in A375 and WM266.4 melanoma cells and, taken
with previous results, this suggests that FMNL2 is likely to
be generally required by melanoma cells for invasion. At
least four alternatively-spliced FMNL2 isoforms are
expressed in primary melanocytes as well as in specific can-
cer cell-lines and sequence analysis of the encoded proteins
suggests they will be targeted by distinct regulatory path-
ways. Of the four isoforms, FMNL2.TQS is preferentially
up-regulated in invasive CRC and melanoma cell-lines and
is the most efficient in supporting cellular invasion. This
raises the possibility that TQS could be considered as an in-
vasive isoform of FMNL2, analogous to MenaINV and the
invasive isoform of palladin. Regardless, our results suggest
that future studies on the role of FMNL2 in metastasis
should concentrate on TQS as the most relevant isoform.
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